+86-28-82633987
Product name: Isomucronulatol
Synonym name:
Catalogue No.: BP0096
Cas No.: 64474-51-7
Formula: C17H18O5
Mol Weight: 302.326
Botanical Source:
Type of Compound:
Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle
Storage: Store in a well closed container, protected from air and light. Put into refrigerate or freeze for long term storage.
Whenever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20℃. Generally, these will be useable for up to two weeks.
The product could be supplied from milligrams to grams
Inquire for bulk scale.
For Reference Standard and R&D, Not for Human Use Directly.
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
69.1700
2.3500
2.1200
Low
.7500
No
No
No
No
No
No
Isomucronulatol (CAS No.: 64474-51-7) is a natural flavonoid derived from the root of the traditional Chinese medicinal material Astragalus membranaceus. As a member of the flavonoid family, isomicroconvex sword leaf sacannol has gradually attracted attention in pharmacology due to its unique chemical structure and biological activity. In recent years, with deeper research into the mechanisms of anti-inflammatory and antitumor effects of natural products, heteromicroconvex sword leaf cyannol has shown potential value in regulating inflammatory responses and various disease-related signaling pathways, especially showing promising application prospects in the prevention and treatment of pretumor lesions such as adenomas.
This review will systematically summarize the chemical structure and physicochemical properties of heterocon swordleaf cyannol, plant origin, and extraction methods, focusing on its pharmacological activity and mechanism of action. Combined with modern drug-making evaluation systems, it explores its clinical application potential and future research directions, aiming to provide theoretical basis and research reference for the drug development of this natural product.
Isomicroconvex swordleaf saconol belongs to the ether class of flavonoids, with a molecular formula of C_17H_18O_6 and a molecular weight of 302.32. The structural features of this compound include a typical flavonoid backbone containing multiple hydroxyl and methoxy substituents, giving it a good polarity and bioactive basis. Its LogP value of 2.35 indicates that the molecule has moderate lipophilus, which facilitates cell membrane penetration without excessive hydrophobicity, fitting the ideal lipophilic range for most oral drugs.
The topological pole surface area (TPSA) is 69.17 Ų, and the number of hydrogen bond acceptors is 5, suggesting that it possesses certain hydrophilicity and binding ability in intermolecular interactions. The low permeability of the blood-brain barrier suggests limited penetration in the central nervous system, which may reduce the risk of central toxicity. Drug-friendly evaluation showed that heteromicroconvex sword leaf serol had no hepatotoxicity, cardiotoxicity, or hERG channel inhibition, was negative in Ames-induced mutagenic tests, and had relatively high safety.
From the perspective of chemical synthesis, the complex flavonoid backbone and polyhydroxyl substituents of heteromicroconvex swordleaf sasol make full synthesis difficult, and currently, it mainly relies on plant extraction and separation for purification.
Isomicroconvex sword leaf satol is mainly isolated from the roots of Astragalus membranaceus. As a traditional Chinese medicinal material, astragalus is widely used in various clinical formulas such as tonifying qi and consolidating the exterior, promoting urination, and reducing swelling. Its roots are rich in various flanonoid compounds, among which the isomicroconvex sword leaf cylindrol is one of the important active components.
The extraction process typically uses alcohol solvents (such as ethanol or methanol) to extract dried Astragalus root powder by reflux, followed by multi-step separation and purification techniques such as liquid-liquid partitioning and column chromatography (silica gel, reversed-phase C18 columns, etc.) to obtain high-purity isomicroconvex sword leaf sand alcohol. High-performance liquid chromatography (HPLC) and mass spectrometry (MS) technologies are commonly used for qualitative and quantitative analysis to ensure the quality and purity of extracts.
In recent years, the application of ultrasound-assisted extraction and microwave-assisted extraction technologies has improved the extraction efficiency and yield of heteromicroconvex sword leaf satrol, providing technical support for its large-scale production.
Isomicroconvex swordleaf santherol demonstrated significant anti-inflammatory activity in in vitro experiments. Studies have shown that this compound can inhibit the expression of the IL-12 p40 subunit in lipopolysaccharide (LPS)-induced macrophages. As a pro-inflammatory cytokine, IL-12 plays a key role in the pathogenesis of various inflammatory diseases. By reducing IL-12 production, isomicroconvex sword leaf cyperol effectively regulates immune responses and alleviates inflammation.
Additionally, there are preliminary reports of the regulatory effects of isomicroconvex sword leaf cylindrol on other inflammatory mediators such as TNF-α and IL-6, suggesting it may exert anti-inflammatory effects through multi-target and multi-pathway synergistic effects.
As a precursor to various malignant tumors, adenomas are closely related to abnormalities in multiple signaling pathways. Isomicroconvex sword leaf synoxylon demonstrates potential anti-adenoma activity by regulating multiple molecular targets associated with adenomas (such as STAT3, SIRT1, NFE2L2, etc.).
The STAT3 signaling pathway plays a key role in tumor cell proliferation, anti-apoptosis, and immune escape. Heteromicroconvex sword leaf satrol may block tumor cell growth signaling by inhibiting STAT3 activation. SIRT1, as a deacetylase, participates in cellular metabolism and stress responses. Its regulation helps maintain cellular homeostasis, and the effects of isomicroconvex sword leaf cylindrol on SIRT1 may mediate its antitumor and anti-aging effects.
Additionally, NFE2L2 (NRF2) is a core transcription factor for cellular antioxidant stress. Isomicroconvex sword leaf cyprosol enhances cellular antioxidant capacity by activating the NFE2L2 pathway, reducing oxidative stress damage, and blocking the malignant transformation of adenoma.
Some studies suggest that heteroconvex sword leaf cyperol may have multiple effects such as regulating lipid metabolism, protecting the liver, and modulating immunity, but the related mechanisms require further elucidation.
The pharmacological action of isomicroconvex swordleaf sersol depends on its regulation of various molecular targets, especially in inflammatory and tumor-related signaling pathways.
The multidimensional regulation of these targets demonstrates the potential of heteromicroconvex sword leaf cyserol as a multi-target drug, especially suitable for the treatment of complex diseases such as inflammatory diseases and tumors.
The druggability parameters of heteromicroconvex sword leaf sartrol indicate that it has good medicinal properties. Moderate molecular weight and LogP value ensure good bioavailability and cell membrane permeability. TPSA and hydrogen bond receptors have moderate numbers, which facilitate binding to target proteins.
In terms of safety, there is no hepatotoxicity, cardiotoxicity, or hERG channel inhibition, and the Ames test is negative, indicating a low genotoxicity risk and suitability for further drug development.
The low permeability of the blood-brain barrier suggests that heterocontinuo sword leaf cyprosol may mainly act on peripheral tissues, reducing the risk of central nervous system side effects.
Currently, pharmacokinetic research on isomicroconvex sword leaf cyannol is limited. Preliminary in vivo experiments suggest it is well absorbed orally and has stable metabolism, mainly excreted through hepatic metabolic pathways. In the future, systematic in vivo pharmacokinetics and toxicology studies are needed to clarify their in vivo behavior and safe dosage ranges.
As the active ingredient in Astragalus, Yiwei Prové Sword Leaf Synol, with its remarkable anti-inflammatory and potential antitumor properties, shows broad clinical application prospects. Its inhibitory effect on LPS-induced IL-12 p40 gives it potential value in treating chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.
In the field of tumor prevention and adjuvant therapy, isolivial sword leaf cyperyl glycol regulates adenoma-related signaling pathways through multiple targets, offering new ideas for adenoma and early tumor intervention. It has good safety and is suitable for long-term use, especially as an adjunct treatment for patients with chronic diseases.
Future research should focus on the following areas:
Through multidisciplinary collaboration, promote the clinical translation of heteromicroconvex sword leaf sand alcohol into a safe and effective new natural medicine.
As a flavonoid derived from astragalus, Isomicroconvex sword leaf sedol demonstrates significant research and application value in anti-inflammatory and anti-tumor fields due to its unique chemical structure and multi-target pharmacological activity. Its excellent druggability parameters and safety lay the foundation for further drug development.
In the future, with further elucidation of pharmacological mechanisms and advances in preclinical research, heteromicroconvex sword leaf sa ol is expected to become a novel candidate for treating inflammatory diseases and pretumor lesions such as adenomas. Ongoing basic research and translational medicine work will provide solid support for its clinical application, promoting innovative development of natural products in modern medicine.
Shenshuai
Wenjing
Hedandan
